It's Showtime for Covidien
Covidien (NYS: COV) is expected to report Q1 earnings on Jan. 25. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Covidien's revenues will grow 3.4% and EPS will drop -6.2%.
The average estimate for revenue is $3.00 billion. On the bottom line, the average EPS estimate is $1.06.
Last quarter, Covidien logged revenue of $3.00 billion. GAAP reported sales were 2.5% lower than the prior-year quarter's $3.08 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.02. GAAP EPS of $0.96 for Q4 were 4.3% higher than the prior-year quarter's $0.92 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 56.0%, 80 basis points worse than the prior-year quarter. Operating margin was 21.3%, 110 basis points worse than the prior-year quarter. Net margin was 15.4%, 70 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $12.39 billion. The average EPS estimate is $4.43.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Covidien is outperform, with an average price target of $64.83.
Is Covidien the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Covidien to My Watchlist.
The article It's Showtime for Covidien originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool recommends Covidien. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.